1. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). National HIV testing policy. February 2017. Available at: (last accessed 18 July 2019).
  1. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Post-exposure prophylaxis after non-occupational and occupational exposure to HIV: Australian National Guidelines (Second edition). August 2016. Available at: (last accessed 18 July 2019).
  1. Robb ML, Eller LA, Kibuuka H, et al. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med 2016;374:2120- 30.
  1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399- 410.
  1. Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013;64:79- 86.
  1. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015;372:509- 18.
  1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423- 34.
  1. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Antiretroviral guidelines: US DHHS guidelines with Australian commentary. Last Updated: 25 October 2018. Available at: (last accessed 23 July 2019).
  1. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016;30:1973-83.
  1. Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug resistance during HIV pre exposure prophylaxis. Drugs 2019;79:609–19.
  1. Parikh UM, Mellors JW. Should we fear resistance from tenofovir/emtricitabine pre-exposure prophylaxis? Curr Opin HIV AIDS 2016;11:49–55.
  1. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505.
  1. Hall AM, Hendry BM, Nitsch D, Connolly JO, Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011;57:773- 80.
  1. Phair J, Palella F, Renal disease in HIV-infected individuals. Curr Opin HIV AIDS 2011;6:285-9.
  1. Solomon MM, Lama JR, Glidden DV, et al; iPrEx Study Team. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 2014;28:851–9.
  1. Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med 2016;176:75–84.
  1. Gandhi M, Glidden D, Mayer K, et al. Age, baseline kidney function, and medication exposure are associated with declines in creatinine clearance on PrEP: an observational cohort study. Lancet HIV 2016;3:e521–e528.
  1. Jotwani V, Scherzer R, Glidden DV, et al. Pre-exposure prophylaxis with tenofovir disoproxil fumarate/ emtricitabine and kidney tubular dysfunction in HIV-uninfected individuals. J Acquir Immune Defic Syndr 2018;78:169-174.
  1. Liegeon G, Antoni G, Pialoux G, et al. Changes in kidney function among MSM initiation on-demand TDF/FTC for HIV PrEP. Paper presented at conference on Retroviruses and Opportunistic Infections (CROI); 4-7 March 2019, Seattle, Washington.
  1. Grant RM, Mannheimer S, Hughes JP, et al. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Clin Infect Dis 2018;66:1712-21.
  1. Hare CB, Coll J, Ruane P, Molina J-M, et al. The Phase 3 Discover Study: daily F/TAF or F/TDF for HIV preexposure prophylaxis. Abstract 104. Retroviruses and Opportunistic Infections (CROI) conference; Seattle, Washington. 4-7 March 2019.
  1. Kidney Health Australia. Chronic Kidney Disease (CKD) Management in General Practice. Guidance and clinical tips to help identify, manage and refer patients with CKD in your practice. 3rd edition. 2015. Available at: (last accessed 18 July 2019).

  1. Australasian Sexual Health Alliance (ASHA). Australian STI management guidelines for use in primary care [internet]. Updated December 2018. Available at: (last accessed 18 July 2019).
  1. Cornelisse VJ, Fairley CK, Stoove M, et al; PrEPX Study Team. Evaluation of preexposure (PrEP) eligibility criteria, using sexually transmissible infections as markers of human immunodeficiency virus (HIV) risk at enrollment in PrEPX, a large Australian HIV PrEP trial. Clin Infect Dis 2018;67:1847-52.
  1. Wolitski RJ , Fenton KA. Sexual health, HIV, and sexually transmitted infections among gay, bisexual, and other men who have sex with men in the United States. AIDS Behav 2011;15:S9-17.
  1. Helm JJ, Prins M, Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 200. AIDS 2011;25:1083-91.
  1. Australian Government Department of Health. Third national hepatitis B strategy 2018–2022. 2018. Available at: (last accessed 18 July 2019).
  1. Australian Government Department of Health. The Australian Immunisation Handbook. Updated 12 April 2019. Available at : (last accessed 23 July 2019).
  1. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLOS ONE 2011; 6:e23688.
  1. Glidden DV, Mulligan K, McMahan V, et al. Brief Report: Recovery of bone mineral density after discontinuation of tenofovir-based HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2017;76:177-182. d
  1. Mulligan K, Glidden DV, Anderson PL, et al; Preexposure Prophylaxis Initiative Study Team. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2015;61:572-80.
  1. Mugo NR, Heffron R, Donnell D, et al; Partners in Prevention HSV/HIV Transmission Study Team. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS 2011; 25:1887–95.
  1. Horgan L, Blyth CC, Bowen AC, Nolan DA, McLean-Tooke AP. Pre-exposure prophylaxis for HIV prevention during pregnancy and lactation: forget not the women and children. Med J Aust 2019;210:281-4.
  1. Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015;61:996-1003.
  1. Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR. The PHACS SMARTT Study: Assessment of the safety of in utero exposure to antiretroviral drugs. Front Immunol 2016;7:199.
  1. Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving pre-exposure prophylaxis for HIV prevention: a randomised clinical trial. JAMA 2014;312:362–71.
  1. Heffron R, Mugo N, Hong T, et al; Partners Demonstration Project and the Partners PrEP Study Teams. Pregnancy outcomes and infant growth among babies with in utero exposure to tenofovir-based pre-exposure prophylaxis for HIV prevention. AIDS 2018;32:1707-13.
  1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Second edition. 2016. Available at: (last accessed 18 July 2019).
  1. Davies N, Heffron R. Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. Sex Health 2018;15:501–12.

40. Cottrell ML, Yang KH, Prince HMA, Sykes C, et al. A translational pharmacology approach to predicting Outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or Without Emtricitabine. The Journal of Infectious Diseases 2016;214

41. Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-Un infected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med 2016;13:e1002132.